Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Uterine Cervical Neoplasms 18Prostatic Neoplasms 18Sarcoma 5Neoplasms 4Uterine Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer 1Retinoblastoma 1Prostate Cancer With Intermediate Risk 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cholangiocarcinoma 1

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Malignant Female Reproductive System Neoplasm × Brachytherapy × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡